About Arranta Bio
Arranta Bio is a Healthcare company based in Watertown (United States) founded in 2019, and was acquired by Recipharm in February 2022. Developer of therapeutics for microbiome based diseases. Arranta Bio has raised $82 million across 1 funding round from investors including Thermo Fisher Scientific, Recipharm and Ampersand Capital Partners. Arranta Bio has completed 1 acquisition, including Captozyme. Its focus areas include Biopharma Outsourcing, CDMO and Biologics. Its competitors include KBI Biopharma, Aldevron and Omnia Biologics; 2 of its 3 listed competitors have raised funding.
Company details
Arrantabio is a contract development and manufacturing organization focusing on the development of therapeutics for the treatment of human microbiome-related diseases. The company develops live biotherapeutic products through bacterial fermentation, isolation, drying, and encapsulation technologies for treating diseases associated with the human microbiome. It offers companies development and cGMP services such as cell banking, frozen blend, drug substance, primary packaging, analytical services and many more.
- Headquarters Watertown, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website arrantabio.com
- Social LinkedIn X
- Acquired by Recipharm (Feb 2022)
- Total Equity Funding$82M (USD)
in 1 rounds
- Latest Funding Round$82M (USD), Series C
Oct 2019
- InvestorsThermo Fisher Scientific
& 2 more
- Investments & Acquisitions
- Acquired byRecipharm
(Feb 2022)
Funding Insights of Arranta Bio
Arranta Bio has successfully raised a total of $82M through 1 strategic funding round. The most recent funding activity was a Series C round of $82 million completed in October 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $82M
- Total Rounds 1
- Last Round Series C — $82M
- First Round $82M
(Oct 2019)
- Investors Count 2
All 1 funding rounds of Arranta Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2019 | $82M | Series C | – | Ampersand Capital, Thermo Fisher Scientific | – |
3 investors in total: 3 institutional.
Investors in Arranta Bio
Arranta Bio has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Thermo Fisher Scientific, Recipharm and Ampersand Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Ampersand Capital Partners is focused on investments in healthcare and life sciences. | ampersandcapital.com | Boston, United States | ||
Electron microscopy services and microanalysis instruments are provided. | 1956 | thermofisher.com | Waltham, United States | |
Pharmaceutical development and manufacturing services are offered contractually. | 1995 | recipharm.com | Jordbro, Sweden |
Investor details for Arranta Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Arranta Bio
56 people are tracked at Arranta Bio (20 in leadership, 8 in board & advisors, 28 in team).
| Name | Role | Group |
|---|---|---|
Peter Venuti | Director of Automation & Technology | Leadership |
Shelly West | Director Of Business Development | Leadership |
Steve Favaloro | Chief Financial Officer | Leadership |
Lana Gladstein | Chief Legal Officer & General Counsel | Leadership |
Aaron Cowley | Chief Scientific Officer | Leadership |
Mark R. Bamforth | Executive Chair & CEO | Leadership |
Dave Stevens | President & Chief Operations Officer | Leadership |
Nick Mazzucca | Director, Business Development | Leadership |
Donna Marston | Strategic Programs Director | Leadership |
Matthew Ulinski, MBA | Associate Director, S&OP & Supply Chain Compliance | Leadership |
Julia Demirali | Controller, Director | Leadership |
Michael Wourms | SVP, Head of Watertown Site Operations | Leadership |
Rich Inman | Site Head Boxborough | Leadership |
Elizabeth Rebeil | Vice President Of Global Supply Chain | Leadership |
Jing Zhu, Ph.D. | VP, Nucleic Acid & Viral Vector Technology | Leadership |
Bill Fox | Head of Site Operations | Leadership |
Iliana Perez-Rivera | Sr. Director Head of GMP Operations | Leadership |
Teresa Neal, Ph.D, MBA | Head of Global Procurement | Leadership |
Xiaojun Liu | Director, Head Of Aav/lv Process Development, Pdna & Mrna, Tech Transfer, Cmc, Pm, Entrepreneurship | Leadership |
Ruth Hill | Head Of Procurement | Leadership |
36 more people are available in the full profile.
Complete people profiles for Arranta Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Arranta Bio
Arranta Bio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Captozyme.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Enzyme-based products for kidney stones and hyperoxaluria are developed. | captozyme.com | Alachua, United States | 2009 | Nov 2019 | •••• |
Complete acquisition details for Arranta Bio
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Competitors of Arranta Bio
Arranta Bio has 3 listed competitors in our database, 2 of them funded. They include KBI Biopharma, Aldevron and Omnia Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kbibiopharma.com | 1996 | Durham, United States | $17M | 1,243 | Provider of protein formulation, process & cell line development, and cGMP services | |
| aldevron.com | 1998 | Fargo, United States | 747 | Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications | ||
| omniabio.com | 2001 | Rockville, United States | $25.4M | Process development and manufacturing services for biologics are provided. |
Detailed competitors of Arranta Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Arranta Bio (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Arranta Bio
Complete news archive for Arranta Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arranta Bio
Arranta Bio was founded in 2019.
Arranta Bio is headquartered in Watertown, United States.
Arranta Bio is a funded company, having raised a total of $82M across 1 funding round to date. The company's 1st funding round was a Series C of $82M, raised on Oct 2019.
Arrantabio is a contract development and manufacturing organization focusing on the development of therapeutics for the treatment of human microbiome-related diseases. The company develops live biotherapeutic products through bacterial fermentation, isolation, drying, and encapsulation technologies for treating diseases associated with the human microbiome. It offers companies development and cGMP services such as cell banking, frozen blend, drug substance, primary packaging, analytical services and many more.
Arranta Bio's top competitors include KBI Biopharma, Aldevron and Omnia Biologics.
Arranta Bio has made 1 acquisition, including Captozyme.
Arranta Bio has 3 investors. Key investors include Thermo Fisher Scientific, Recipharm, and Ampersand Capital Partners.
Yes. Arranta Bio was acquired by Recipharm in February 2022.